GTX INITIATES TRIAL OF ACAPODENE

A A

GTx has launched a Phase IIIb clinical trial as an extension of the pivotal Phase III ADT clinical trial of Acapodene in an 80 mg dose to treat multiple serious side effects of androgen deprivation therapy. The primary endpoint of the trial is a reduction in vertebral fractures. The main aim of the study is to collect additional efficacy and safety data that could further support the current Phase III clinical study.

The interim analysis showed a highly statistically significant positive change in bone mineral density in patients treated with Acapodene versus patients on placebo.